Microfluidic Transduction Harnesses Mass Transport Principles to Enhance Gene Transfer Efficiency.

ABSTRACT: Ex vivo gene therapy using lentiviral vectors (LVs) is a proven approach to treat and potentially cure many hematologic disorders and malignancies but remains stymied by cumbersome, cost-prohibitive, and scale-limited production processes that cannot meet the demands of current clinical protocols for widespread clinical utilization. However, limitations in LV manufacture coupled with inefficient transduction protocols requiring significant excess amounts of vector currently limit widespread implementation. Herein, we describe a microfluidic, mass transport-based approach that overcomes the diffusion limitations of current transduction platforms to enhance LV gene transfer kinetics and efficiency. This novel ex vivo LV transduction platform is flexible in design, easy to use, scalable, and

SUBMITTER: Tran R 

PROVIDER: S-EPMC5628863 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature